èšåºæ®µéã®ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãã Equillium, Inc. ã¯ãå»çããŒãºãæºããããŠããªãé床ã®èªå·±å
ç«çŸæ£ãççæ§çŸæ£ããŸãã¯å
ç«ççæ§çŸæ£ã®æ²»çè¬ã®éçºãšè²©å£²ãè¡ã£ãŠããŸããäž»ãªè£œååè£ã¯ã€ããªãºããã§ããããã¯ãæ°èŠå
ç«ãã§ãã¯ãã€ã³ãåå®¹äœ CD6 ãæšçãšããèšåºæ®µéã®ã¢ãã¯ããŒãã«æäœã§ãæ¥æ§ç§»æ€ç察宿䞻ç
ã®æ²»çè¬ãšããŠç¬¬ 1b/2 çžèšåºè©Šéšãããã³åæ¯ãšã«ãŒãã¹è
çã®æ²»çè¬ãšããŠç¬¬ 1 çžèšåºè©Šéšãè¡ãããŠããŸããå瀟ã¯ä»¥å㯠Attenuate Biopharmaceuticals, Inc. ãšããŠç¥ãããŠããŸãããã2017 幎 5 æã« Equillium, Inc. ã«ç€Ÿåã倿ŽããŸãããEquillium, Inc. 㯠2017 幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ã©ãã€ã«æ¬ç€Ÿã眮ããŠããŸãã